Lyell Immunopharma, Inc. (LYEL) Guidance & Earnings Results
On 2026-03-12 Lyell Immunopharma, Inc. reaffirmed guidance: "Cash runway into Q2 2027; pivotal data expected mid-next…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LYELLyell Immunopharma, Inc.Follow LYEL — free
—
Price chart with a free account
- Market cap
- 230.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 12 Mar 26 | Reaffirmed | Cash runway into Q2 2027; pivotal data expected mid-next year. · full year |
Lyell Immunopharma, Inc. — questions
- What guidance did Lyell Immunopharma, Inc. give?
- On 2026-03-12: "Cash runway into Q2 2027; pivotal data expected mid-next year."
- When does Lyell Immunopharma, Inc. report earnings?
- Lyell Immunopharma, Inc.'s next earnings report is expected on 2026-11-09.
Every figure on this page comes from Lyell Immunopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.